![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 26-Apr-2013[ | E-mail |
Share ] Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Amsterdam, The Netherlands, Friday 26 April 2013: A study presented today at the International Liver CongressTM 2013 which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.
NAFLD is one of the most common causes of chronic liver disease. Patients with NAFLD have an excess prevalence of CV events and typically have an increase frequency of risk factors already known to be directly related to atherosclerosis. As a consequence, it remains unclear if the presence of fatty liver should be regarded as an independent risk factor for CV disease.
Over 5000 patients with two or more traditional CV risk factors (without previous CV events), low alcohol intake (1,5 mm at carotid bifurcation. The Fatty Liver Index (FLI), a surrogate marker of hepatic steatosis when >60, and the Framingham score (FRS) were calculated.
Patients with a FLI of 60 or more also had a higher BMI and increased levels of liver enzymes (ALT, AST, GGT) (p
This study demonstrated that NAFLD is highly prevalent in patients at high risk of CV diseases and is an independent predictor of early atherosclerosis and 10-years CV risk beyond classical CV risk factors. These findings strengthen the evidence that NAFLD is a heterogeneous entity requiring a multidisciplinary approach and modified screening strategies.
Type-2 diabetes and dyslipidemia are known risk factors usually associated with cardiovascular and liver-related deaths in NAFLD. A second study presented today evaluated the 10-year prognostic value of non-invasive markers FibroTest and SteatoTest for overall survival (OS), survival without liver-related death (LRD) and cardiovascular-related death (CVD) in patients with diabetes and/or dyslipidemia without known liver disease.
Over 2000 patients were prospectively followed for 12 years and mortality data collected. The study found in diabetics, regardless of associated hyperlipidaemia, FibroTest had a significant 10-year prognostic value for the overall and without liver-related death survivals. SteatoTest was also predictive of CV-related death in hyperlipidemia patients.
Both OS and survival without CVD were significantly higher in the hyperlipidemia group than in the diabetic or diabetic with hyperlipidemia group. The hyperlipidemia group with advanced steatosis (AS) tested by Steatotest had lower survival without-CVD, compared to non-AS: 97(94-99) vs. 99(98-99, P=0.004). FibroTest remained significant for the prediction of OS in the diabetic group [risk ratio (RR) = 136.9 (95%CI 11.6-1610; P
The study concluded that patients with type-2 diabetes, especially those with associated hyperlipidemia, presented particularly higher rates of advanced fibrosis and steatosis as well as higher overall and liver-related mortalities than those with isolated hyperlipidemia.
EASL's Education Councillor, Jean-Francois Dufour commented. "These studies reinforce the view that in patients with other risk factors such as diabetes or other metabolic impairment, the degree of liver fat deposition is an important determinant of long term mortality, not only due to liver disease progression, but other causes, particularly cardiovascular events. Although patients with NAFLD have long been known to suffer from excess cardiovascular disease, it was uncertain if this was mediated through a higher risk of earlier atherosclerotic lesions. These studies show that NAFLD is an independent predictor of cardiovascular risk."
Disclaimer: the data referenced in this release is based on the submitted abstract. More recent data may be presented at the International Liver Congress 2013.
###
Notes to Editors
About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL's main focus on education and research is delivered through numerous events and initiatives, including:
- The International Liver CongressTM which is the main scientific and professional event in
hepatology worldwide
- Meetings including Monothematic and Special conferences, Post Graduate courses and other
endorsed meetings that take place throughout the year
- Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field
of hepatology
- Journal of Hepatology published monthly
- Participation in a number of policy initiatives at European level
About The International Liver Congress 2013
The International Liver Congress 2013, the 48th annual meeting of the European Association for the study of the Liver, is being held at the RAI Convention Centre in Amsterdam from April 24 28, 2013. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
References:
1 Pais R et al, NAFLD IS SIGNIFICANTLY INCREASED IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS AND IS CORRELATED WITH EARLY PREDICTORS OF ATHEROSCLEROSIS AND THE FRAMINGHAM SCORE. Presented at the International Liver Congress 2013
2 Perazzo H et al, 10-YEARS PROGNOSTIC VALUE OF FIBROTEST AND STEATOTEST FOR LIVER-RELATED AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE-2 DIABETES AND/OR HYPERLIPIDEMIA. Presented at the International Liver Congress 2013
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 26-Apr-2013[ | E-mail |
Share ] Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Amsterdam, The Netherlands, Friday 26 April 2013: A study presented today at the International Liver CongressTM 2013 which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.
NAFLD is one of the most common causes of chronic liver disease. Patients with NAFLD have an excess prevalence of CV events and typically have an increase frequency of risk factors already known to be directly related to atherosclerosis. As a consequence, it remains unclear if the presence of fatty liver should be regarded as an independent risk factor for CV disease.
Over 5000 patients with two or more traditional CV risk factors (without previous CV events), low alcohol intake (1,5 mm at carotid bifurcation. The Fatty Liver Index (FLI), a surrogate marker of hepatic steatosis when >60, and the Framingham score (FRS) were calculated.
Patients with a FLI of 60 or more also had a higher BMI and increased levels of liver enzymes (ALT, AST, GGT) (p
This study demonstrated that NAFLD is highly prevalent in patients at high risk of CV diseases and is an independent predictor of early atherosclerosis and 10-years CV risk beyond classical CV risk factors. These findings strengthen the evidence that NAFLD is a heterogeneous entity requiring a multidisciplinary approach and modified screening strategies.
Type-2 diabetes and dyslipidemia are known risk factors usually associated with cardiovascular and liver-related deaths in NAFLD. A second study presented today evaluated the 10-year prognostic value of non-invasive markers FibroTest and SteatoTest for overall survival (OS), survival without liver-related death (LRD) and cardiovascular-related death (CVD) in patients with diabetes and/or dyslipidemia without known liver disease.
Over 2000 patients were prospectively followed for 12 years and mortality data collected. The study found in diabetics, regardless of associated hyperlipidaemia, FibroTest had a significant 10-year prognostic value for the overall and without liver-related death survivals. SteatoTest was also predictive of CV-related death in hyperlipidemia patients.
Both OS and survival without CVD were significantly higher in the hyperlipidemia group than in the diabetic or diabetic with hyperlipidemia group. The hyperlipidemia group with advanced steatosis (AS) tested by Steatotest had lower survival without-CVD, compared to non-AS: 97(94-99) vs. 99(98-99, P=0.004). FibroTest remained significant for the prediction of OS in the diabetic group [risk ratio (RR) = 136.9 (95%CI 11.6-1610; P
The study concluded that patients with type-2 diabetes, especially those with associated hyperlipidemia, presented particularly higher rates of advanced fibrosis and steatosis as well as higher overall and liver-related mortalities than those with isolated hyperlipidemia.
EASL's Education Councillor, Jean-Francois Dufour commented. "These studies reinforce the view that in patients with other risk factors such as diabetes or other metabolic impairment, the degree of liver fat deposition is an important determinant of long term mortality, not only due to liver disease progression, but other causes, particularly cardiovascular events. Although patients with NAFLD have long been known to suffer from excess cardiovascular disease, it was uncertain if this was mediated through a higher risk of earlier atherosclerotic lesions. These studies show that NAFLD is an independent predictor of cardiovascular risk."
Disclaimer: the data referenced in this release is based on the submitted abstract. More recent data may be presented at the International Liver Congress 2013.
###
Notes to Editors
About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL's main focus on education and research is delivered through numerous events and initiatives, including:
- The International Liver CongressTM which is the main scientific and professional event in
hepatology worldwide
- Meetings including Monothematic and Special conferences, Post Graduate courses and other
endorsed meetings that take place throughout the year
- Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field
of hepatology
- Journal of Hepatology published monthly
- Participation in a number of policy initiatives at European level
About The International Liver Congress 2013
The International Liver Congress 2013, the 48th annual meeting of the European Association for the study of the Liver, is being held at the RAI Convention Centre in Amsterdam from April 24 28, 2013. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
References:
1 Pais R et al, NAFLD IS SIGNIFICANTLY INCREASED IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS AND IS CORRELATED WITH EARLY PREDICTORS OF ATHEROSCLEROSIS AND THE FRAMINGHAM SCORE. Presented at the International Liver Congress 2013
2 Perazzo H et al, 10-YEARS PROGNOSTIC VALUE OF FIBROTEST AND STEATOTEST FOR LIVER-RELATED AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE-2 DIABETES AND/OR HYPERLIPIDEMIA. Presented at the International Liver Congress 2013
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/eaft-n1r042513.php
marijuana Colorado Marijuana elizabeth warren puerto rico diane sawyer Washington Election Results drudge report
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.